As the marrow suddenly starts making new cells aggressively, potassium shifts intracellularly and serum levels can fall fast
Three to four injections can be performed within a 12-month period
Oral supplements: can work for mild deficiency and maintenance in people who absorb B12 normally, but tend to take longer and are less reliable when absorption is impaired
This slightly acidic environment also aids peptide solubility and stability
Report anything persistent or severe to your provider, who monitors your response throughout treatment
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
